JP2023541456A5 - - Google Patents

Info

Publication number
JP2023541456A5
JP2023541456A5 JP2023516737A JP2023516737A JP2023541456A5 JP 2023541456 A5 JP2023541456 A5 JP 2023541456A5 JP 2023516737 A JP2023516737 A JP 2023516737A JP 2023516737 A JP2023516737 A JP 2023516737A JP 2023541456 A5 JP2023541456 A5 JP 2023541456A5
Authority
JP
Japan
Prior art keywords
cells
cell
nucleic acid
acid molecule
isolated nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023516737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541456A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/050331 external-priority patent/WO2022056490A1/en
Publication of JP2023541456A publication Critical patent/JP2023541456A/ja
Publication of JP2023541456A5 publication Critical patent/JP2023541456A5/ja
Pending legal-status Critical Current

Links

JP2023516737A 2020-09-14 2021-09-14 がん治療用キメラ抗原受容体 Pending JP2023541456A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063078237P 2020-09-14 2020-09-14
US63/078,237 2020-09-14
PCT/US2021/050331 WO2022056490A1 (en) 2020-09-14 2021-09-14 Chimeric antigen receptors for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2023541456A JP2023541456A (ja) 2023-10-02
JP2023541456A5 true JP2023541456A5 (https=) 2024-09-26

Family

ID=78414716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516737A Pending JP2023541456A (ja) 2020-09-14 2021-09-14 がん治療用キメラ抗原受容体

Country Status (4)

Country Link
US (1) US20230372484A1 (https=)
EP (1) EP4210832A1 (https=)
JP (1) JP2023541456A (https=)
WO (1) WO2022056490A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023010118A1 (en) * 2021-07-29 2023-02-02 Vor Biopharma Inc. Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
ATE511400T1 (de) 2000-03-03 2011-06-15 Genetronics Inc Nukleinsäure-fomulierungen zur genverabreichung
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US20040014645A1 (en) 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20050070841A1 (en) 2002-07-04 2005-03-31 Inovio As Electroporation device and injection apparatus
AU2006342101A1 (en) 2005-12-07 2007-10-25 Genetronics, Inc Variable volume electroporation chamber and methods therefore
EP2655624B1 (en) 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
EP3131927B8 (en) * 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
TWI719942B (zh) * 2014-07-21 2021-03-01 瑞士商諾華公司 使用cd33嵌合抗原受體治療癌症
AU2016337525B2 (en) 2015-10-16 2022-01-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
ES2981703T3 (es) * 2016-09-02 2024-10-10 Lentigen Tech Inc Composiciones y métodos para tratar cáncer con DuoCars
US12053490B2 (en) * 2017-10-26 2024-08-06 St. Jude Children's Research Hospital, Inc. Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cells
GB201721833D0 (en) * 2017-12-22 2018-02-07 Cancer Research Tech Ltd Fusion proteins
EA202092044A1 (ru) 2018-03-14 2021-03-03 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные рецепторы антигена против cd33 и их применения
WO2020051013A2 (en) * 2018-08-24 2020-03-12 The Trustees Of Columbia University In The City Of New York Anti-cd33 and nkg2d ligand chimeras for treatment of myeloid malignancies
EP3850013A4 (en) * 2018-09-10 2022-10-05 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND USES THEREOF
JP2022510218A (ja) * 2018-11-30 2022-01-26 メモリアル スローン ケタリング キャンサー センター ヘテロ二量体四価特異性抗体およびこれらの使用
EP3908613A4 (en) * 2019-01-07 2022-10-19 Celluris Participações Ltda. BISPECIFIC IN-TANDEM RECEPTOR CAR AND METHODS FOR MODULATION OF THE TUMOR MICROAREA

Similar Documents

Publication Publication Date Title
US12018077B2 (en) Methods of treatments using antigen-binding proteins targeting CD56
CN108715859B (zh) 靶向cd22的嵌合抗原受体及其应用
AU2016297014B2 (en) Methods for improving the efficacy and expansion of immune cells
JP2023139070A5 (https=)
AU2016382512A1 (en) Immune effector cell therapies with enhanced efficacy
KR20190036551A (ko) Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료
JP2017512054A (ja) 三官能性t細胞−抗原カプラ及び方法並びにこれらの使用
JP2018518459A5 (https=)
KR20230130148A (ko) Cd20 결합 분자 및 그의 용도
KR102834084B1 (ko) 다양한 구조 최적화를 갖는 t 세포-항원 커플러
KR20200020677A (ko) 유전자 치료법
JP7437705B2 (ja) 抗cd38及び抗cd138キメラ抗原受容体を含むt細胞、及びその用途
EP3710020A1 (en) Il-36 secreting immunoresponsive cells and uses thereof
EP3526257A2 (en) Modular tetravalent bispecific antibody platform
CN110157738B (zh) 靶向cd19和cd22的工程化免疫细胞及其应用
EP4121518A1 (en) Engineered cell compositions and methods of use thereof
WO2019192526A1 (zh) 嵌合抗原受体和其治疗癌症的方法
KR20230106153A (ko) CD47-SIRPα 차단제를 이용하여 안전성 사멸 메커니즘을 촉발하기 위한 방법
EP3849565A1 (en) Reducing cd33 expression to selectively protect therapeutic cells
CA3082560A1 (en) Il-33 secreting immunoresponsive cells and uses thereof
KR20230147109A (ko) Her2 양성 암을 치료하기 위한 조성물 및 방법
JP2023541456A5 (https=)
CN117529505A (zh) 设计为减少逆转录病毒重组的双顺反子嵌合抗原受体及其用途
KR20240004680A (ko) 키메라 수용체 및 이의 사용 방법
CN111850014A (zh) 一种细胞因子增效的嵌合抗原受体及其应用